New hope for liver cancer? early trial combines two drugs
NCT ID NCT07478302
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tests a new drug called SHR-2524 combined with bevacizumab in 36 people with advanced liver cancer that hasn't been treated before. The main goals are to check safety, how the body processes the drugs, and to get an early look at whether the combination might shrink tumors. It's a Phase 1 study, so it's too soon to know if this will become a standard treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-2524 injection and bevacizumab injection
- What this could lead to
- If successful, this could point toward a new combination therapy for advanced liver cancer that hasn't been treated before.
- What could go wrong
- This is a very early Phase 1 trial with only 36 people, so it's mainly checking safety and dosing. The drug may not work or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mengchao Hepatobiliary Hospital of Fujian Medical University
RECRUITINGFuzhou, Fujian, 350002, China
-
The First Affiliated Hospital of Guangxi Medical University
RECRUITINGNanning, Guangxi, 530021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.